- ImmunityBio is preparing to submit their BLA in NMIBC in the first quarter of 2022. The company is moving forward with several COVID-19 vaccine programs with different technologies.
- The company recently secured $300M in new debt financing from Dr. Patrick Soon-Shiong’s NantCapital. The company is now well funded and will halt their ATM activity.
- The company has worked hard to increase the manufacturing capacity for their products, including RNA, DNA, subunit proteins, and adjuvants in U.S., South Africa, and Botswana.
- ImmunityBio has thirteen ongoing Phase II/III clinical trials in oncology indications, COVID, and HIV. I review the company’s progress in 2021 and why I am extremely bullish on 2022.
For further details see:
ImmunityBio: Company Leaves 2021 On A High-Note; Share Price Still Falls Flat